sr pharma plc new drug application receives fda approval biopharmaceuticals company sr pharma plc said the u s food and drug administration approved an investigational new drug application to treat acute kidney injuries the product akii is licensed to quark biotech inc while sr pharma retains the patent the u k based company said akii is quarks lead product candidate to prevent acute kidney injuries in high risk patients undergoing major cardiovascular surgery sr pharma can now begin testing akii on humans 
